Breaking News

Lonza, BioWa Ink Cell Line Technology Pact with arGEN-X

Will use POTELLIGENT CHOK1SV for antibody development

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioWa, Inc. and Lonza have entered into a licensing agreement with arGEN-X BV, under which arGEN-X will have access to the companies’ POTELLIGENT CHOK1SV Cell Line Technology for the development of ARGX-110, a monoclonal antibody targeting CD70 positive tumors.   POTELLIGENT CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation POTELLIGENT Technology with Lonza’s GS Gene Expression System that includes the CHOK1SV host cell line. The ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters